01_alina-2

fullsizerender-3

nehi2

Patients in need of cholesterol lowering therapy are not being granted access to it, according to a novel data analysis by the Familial Hypercholesterolemia Foundation. (PRNewsfoto/The FH Foundation)

FH Foundation’s FOCUS analysis shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates

1 Comment

Pasadena, Calif. – The Familial Hypercholesterolemia Foundation today published a study in Circulation revealing high rejection rates for PCSK9 inhibitors in the two at-risk patient populations approved for this novel cholesterol-lowering class of therapy.

The FH Foundation’s FOCUS (FH Optimal … Read More


sweeney_colleen_20150410_np_fh_880-ssedit

mccready_colleen_20150410_np_fh_751

01_Alina 2

screen-shot-2017-04-05-at-1-45-22-pm

screen-shot-2017-03-30-at-10-34-57-am

01_Alina 2

1 2 3 8